- Death toll in Brazil bus crash rises to 41
- Odermatt stays hot to break Swiss World Cup wins record
- Neville says Rashford's career at Man Utd nearing 'inevitable ending'
- Syria's new leader vows not to negatively interfere in Lebanon
- Germany pledges security inquest after Christmas market attack
- Putin vows 'destruction' on Ukraine after Kazan drone attack
- Understated Usyk seeks recognition among boxing legends
- France awaits appointment of new government
- Cyclone Chido death toll rises to 94 in Mozambique
- Stokes out of England's Champions Trophy squad
- Gaza rescuers say Israeli strikes kill 28
- Sweet smell of success for niche perfumes
- 'Finally, we made it!': Ho Chi Minh City celebrates first metro
- Angry questions in Germany after Christmas market attack
- China's Zheng pulls out of season-opening United Cup
- Minorities fear targeted attacks in post-revolution Bangladesh
- Tatum's 43-point triple-double propels Celtics over Bulls
- Tunisia women herb harvesters struggle with drought and heat
- Trump threatens to take back control of Panama Canal
- India's architecture fans guard Mumbai's Art Deco past
- Secretive game developer codes hit 'Balatro' in Canadian prairie province
- Large earthquake hits battered Vanuatu
- Beaten Fury says Usyk got 'Christmas gift' from judges
- First Singaporean golfer at Masters hopes 'not be in awe' of heroes
- Usyk beats Fury in heavyweight championship rematch
- Stellantis backtracks on plan to lay off 1,100 at US Jeep plant
- Atletico snatch late win at Barca to top La Liga
- Australian teen Konstas ready for Indian pace challenge
- Strong quake strikes off battered Vanuatu
- Tiger Woods and son Charlie share halfway lead in family event
- Bath stay out in front in Premiership as Bristol secure record win
- Mahomes shines as NFL-best Chiefs beat Texans to reach 14-1
- Suspect in deadly Christmas market attack railed against Islam, Germany
- MLB legend Henderson, career stolen base leader, dead at 65
- Albania announces shutdown of TikTok for at least a year
- Laboured Napoli take top spot in Serie A
- Schick hits four as Leverkusen close gap to Bayern on sombre weekend
- Calls for more safety measures after Croatia school stabbings
- Jesus double lifts Christmas spirits for five-star Arsenal
- Frankfurt miss chance to close on Bayern as attack victims remembered
- NBA fines Celtics coach Mazzulla and Nets center Claxton
- Banned Russian skater Valieva stars at Moscow ice gala
- Leading try scorer Maqala takes Bayonne past Vannes in Top 14
- Struggling Southampton appoint Juric as new manager
- Villa heap pain on slumping Man City as Forest soar
- Suspect in deadly Christmas market attack railed against Islam and Germany
- At least 32 die in bus accident in southeastern Brazil
- Freed activist Paul Watson vows to 'end whaling worldwide'
- Chinese ship linked to severed Baltic Sea cables sets sail
- Sorrow and fury in German town after Christmas market attack
US FDA says Pfizer Covid vaccine effective in kids under five
The US Food and Drug Administration (FDA) has said the Pfizer Covid vaccine is safe and effective in children under five, ahead of a meeting to weigh its authorization later this week.
Children under five are the only age group not yet eligible for vaccination in the United States and most countries, a pressing need since rates of hospitalization and death "are higher than among children and adolescents 5-17 years of age," the FDA said in a document posted on its website Sunday.
The agency has called a meeting of experts on June 15 to decide whether to recommend the Pfizer vaccine, given as three shots to children aged six months through four years, as well as the Moderna vaccine, given as two shots to children aged six months through five years.
Pfizer's first two shots are given three weeks apart, then the third is given eight weeks after the second. They are all dosed at three micrograms, as opposed to 30 micrograms the company gives older ages.
Both Pfizer and Moderna had previously posted their results, but the FDA then had to review the data in detail and carry out its own evaluation. It posted a favorable analysis about Moderna on Friday.
Its comments towards Pfizer also appear favorable, based on the levels of infection-blocking antibodies it evoked in trial participants, and a similar side-effect profile to higher age groups. The trial population was around 4,500 children.
A preliminary estimate placed vaccine efficacy at 80.3 percent, but the FDA noted this was based on very few positive cases -- just 10, as opposed to the 21 sought for a more accurate figure.
There are nearly 20 million US children aged four years and under, or six percent of the population. If, as expected, the FDA-appointed experts recommend the two shots, then the matter will go to another committee convened by the Centers for Disease Control and Prevention for a final say.
White House officials last week said rollout of millions of shots at pharmacies and doctors' offices could begin as soon as June 21, following the Juneteenth holiday on June 20.
P.L.Madureira--PC